Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Ferring Pharmaceuticals, Inc. Snapshot 6
Ferring Pharmaceuticals, Inc. Overview 6
Key Information 6
Key Facts 6
Ferring Pharmaceuticals, Inc. – Research and Development Overview 7
Key Therapeutic Areas 7
Ferring Pharmaceuticals, Inc. – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products – Monotherapy 10
Ferring Pharmaceuticals, Inc. – Pipeline Products Glance 11
Ferring Pharmaceuticals, Inc. – Late Stage Pipeline 11
Registration Filed Products/Combination Treatment Modalities 11
Phase III Products/Combination Treatment Modalities 12
Ferring Pharmaceuticals, Inc. Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Ferring Pharmaceuticals, Inc. – Early Stage Pipeline Products 14
Pre-Clinical Products/Combination Treatment Modalities 14
Ferring Pharmaceuticals, Inc. – Drug Profiles 15
Barusiban 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Budesonide MMX 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Degarelix 3 month Formulation 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
FE 202158 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
FE301 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Firmagon 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Ferring Pharmaceuticals, Inc. – Pipeline Analysis 22
Ferring Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class 22
Ferring Pharmaceuticals, Inc. – Pipeline Products By Target 24
Ferring Pharmaceuticals, Inc. – Pipeline Products by Route of Administration 25
Ferring Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action 26
Ferring Pharmaceuticals, Inc. – Recent Pipeline Updates 27
Ferring Pharmaceuticals, Inc. - Dormant Projects 29
Ferring Pharmaceuticals, Inc. – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Ferring Pharmaceuticals, Inc., Recent Developments 31
Ferring Pharmaceuticals, Inc.- Press Release 31
Mar 02, 2012: CMX Research Initiates Phase IV DELAY Study 31
Feb 28, 2012: New Data Demonstrates FIRMAGON''s Non-inferiority To Combination Of Goserelin Plus Bicalutamide At Reducing Prostate Volume In Patients With Advanced Hormone-Dependent Prostate Cancer 31
Dec 21, 2009: FIRMAGON has a significantly greater probability of PSA recurrence-free survival than leuprolide in prostate cancer patients 32
Dec 04, 2009: Ferring Pharmaceuticals Announces Phase III Pivotal Study Results Of FIRMAGON For The Treatment Of Prostate Cancer 33
Nov 16, 2009: Xanodyne announces FDA approval of Lysteda (tranexamic acid) for the treatment of women with heavy menstrual bleeding. 33
Oct 20, 2009: Research compares Menopur with rFSH in GNRH antagonist IVF cycles 34
Aug 04, 2009: Ferring Pharmaceuticals Announces Trade Name FIRMAGON For Advanced Prostate Cancer Treatment 34
Jun 30, 2009: New Data Supports Significant Economic and Clinical Value of Menopur in Invitro fertilization (IVF). 35
Apr 27, 2009: Ferring Pharmaceuticals launches Phase IIIB Trial Of Degarelix As Intermittent Therapy 36
Mar 18, 2009: Firmagon (degarelix) is launched in Europe for the treatment of advanced prostate cancer 37
Mar 04, 2009: Ferring Pharmaceuticals, Inc. Announces Immediate Availability Of Degarelix For The Treatment Of Cancer 38
Feb 19, 2009: European Commission grants Ferring Pharmaceuticals approval of Firmagon (degarelix) for treatment of prostate cancer 39
Financial Deals Landscape 40
Ferring Pharmaceuticals, Inc., Deals Summary 40
Ferring Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details 42
Asset Transactions 42
Ferring Pharma Acquires Norprolac From Novartis Pharma 42
Partnerships 43
TIMM Medical Enters Into Co-Promotion Agreement With Ferring Pharma 43
Ferring Pharma Enters Into Distribution Agreement With BioGaia 44
Savient Signs Agreement With Ferring Pharma 45
Savient Pharma Enters Into Co-Promotion Agreement With Ferring Pharma 46
Licensing Agreements 47
Ferring Pharma Enters Into Licensing Agreement With Cosmo Pharma 47
Crucell And DSM Biologics Enter Into Licensing Agreement With Ferring Pharma 49
Ferring Pharma Enters Into Licensing Agreement With CONARIS Research Institute 50
Crucell And DSM Enter Into Licensing Agreement With Ferring 51
Ferring Pharma Enters Into Licensing Agreement With Vyteris 52
Asset Transactions 53
Shanghai Dongbao Acquires Manufacturing Operation From Ferring Pharma 53
Acquisition 54
Ferring Pharma Acquires Cytokine PharmaSciences And Controlled Therapeutics 54
Ferring Pharma Acquires Dupomar 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58
List of Tables
Ferring Pharmaceuticals, Inc., Key Information 6
Ferring Pharmaceuticals, Inc., Key Facts 6
Ferring Pharmaceuticals, Inc. – Pipeline by Indication, 2012 8
Ferring Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012 9
Ferring Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012 10
Ferring Pharmaceuticals, Inc. – Filed, 2012 11
Ferring Pharmaceuticals, Inc. – Phase III, 2012 12
Ferring Pharmaceuticals, Inc. – Phase II, 2012 13
Ferring Pharmaceuticals, Inc. – Pre-Clinical, 2012 14
Ferring Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012 23
Ferring Pharmaceuticals, Inc. - Pipeline By Target, 2012 24
Ferring Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012 25
Ferring Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2012 26
Ferring Pharmaceuticals, Inc. – Recent Pipeline Updates, 2012 27
Ferring Pharmaceuticals, Inc. - Dormant Developmental Projects,2012 29
Ferring Pharmaceuticals, Inc., Other Locations 30
Ferring Pharmaceuticals, Inc., Deals Summary 40
Ferring Pharma Acquires Norprolac From Novartis Pharma 42
TIMM Medical Enters Into Co-Promotion Agreement With Ferring Pharma 43
Ferring Pharma Enters Into Distribution Agreement With BioGaia 44
Savient Signs Agreement With Ferring Pharma 45
Savient Pharma Enters Into Co-Promotion Agreement With Ferring Pharma 46
Ferring Pharma Enters Into Licensing Agreement With Cosmo Pharma 47
Crucell And DSM Biologics Enter Into Licensing Agreement With Ferring Pharma 49
Ferring Pharma Enters Into Licensing Agreement With CONARIS Research Institute 50
Crucell And DSM Enter Into Licensing Agreement With Ferring 51
Ferring Pharma Enters Into Licensing Agreement With Vyteris 52
Shanghai Dongbao Acquires Manufacturing Operation From Ferring Pharma 53
Ferring Pharma Acquires Cytokine PharmaSciences And Controlled Therapeutics 54
Ferring Pharma Acquires Dupomar 56
List of Figures
Ferring Pharmaceuticals, Inc. – Pipeline by Indication, 2012 8
Ferring Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2012 9
Ferring Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2012 10
Ferring Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2012 22
Ferring Pharmaceuticals, Inc. - Pipeline By Target, 2012 24
Ferring Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2012 25
Ferring Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2012 26